Patient Safety Organizations: Expired Listing From Premerus PSO, LLC, 15220 [2015-06454]
Download as PDF
<![CDATA[
15220
Federal Register / Vol. 80, No. 55 / Monday, March 23, 2015 / Notices
Type of
respondent
Form name
Risk Factor Assessment ..........................................................
Dated: March 11, 2015.
Lynn Susulske,
NHLBI Project Clearance Liaison, National
Institutes of Health.
BILLING CODE 4141–01–P
Background
Agency for Healthcare Research and
Quality
Patient Safety Organizations: Expired
Listing From Premerus PSO, LLC
Agency for Healthcare Research
and Quality (AHRQ), Department of
Health and Human Services (HHS).
ACTION: Notice of delisting.
AGENCY:
The Patient Safety and
Quality Improvement Act of 2005, 42
U.S.C. 299b–21 to b–26, (Patient Safety
Act) and the related Patient Safety and
Quality Improvement Final Rule, 42
CFR part 3 (Patient Safety Rule),
published in the Federal Register on
November 21, 2008, (73 FR 70732–
70814), provide for the formation of
Patient Safety Organizations (PSOs),
which collect, aggregate, and analyze
confidential information regarding the
quality and safety of healthcare
delivery. The Patient Safety Rule
authorizes AHRQ, on behalf of the
Secretary of HHS, to list as a PSO an
entity that attests that it meets the
statutory and regulatory requirements
for listing. A PSO can be ‘‘delisted’’ by
the Secretary if it is found to no longer
meet the requirements of the Patient
Safety Act and Patient Safety Rule,
when a PSO chooses to voluntarily
relinquish its status as a PSO for any
reason, or when a PSO’s listing expires.
The listing from the Premerus PSO, LLC
has expired and AHRQ has delisted the
PSO accordingly.
DATES: The directories for both listed
and delisted PSOs are ongoing and
reviewed weekly by AHRQ. The
delisting was effective at 12:00 Midnight
ET (2400) on January 10, 2015.
ADDRESSES: Both directories can be
accessed electronically at the following
HHS Web site: https://
www.pso.AHRQ.gov/.
FOR FURTHER INFORMATION CONTACT:
Eileen Hogan, Center for Quality
mstockstill on DSK4VPTVN1PROD with NOTICES
16:51 Mar 20, 2015
Jkt 235001
Dated: March 17, 2015.
Sharon B. Arnold,
Deputy Director, AHRQ.
[FR Doc. 2015–06454 Filed 3–20–15; 8:45 am]
BILLING CODE 4160–90–P
Frm 00035
1
Fmt 4703
Sfmt 4703
Average
burden per
response
(in hours)
Total
annual
burden
hour
19/60
40
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Commercial License Agreement:
Development of 5T4 Antibody-Drug
Conjugates for the Treatment of
Human Cancers
AGENCY:
The Patient Safety Act authorizes the
listing of PSOs, which are entities or
component organizations whose
mission and primary activity are to
conduct activities to improve patient
safety and the quality of health care
delivery.
HHS issued the Patient Safety Rule to
implement the Patient Safety Act.
AHRQ administers the provisions of the
Patient Safety Act and Patient Safety
Rule relating to the listing and operation
of PSOs. The Patient Safety Rule
authorizes AHRQ to list as a PSO an
entity that attests that it meets the
statutory and regulatory requirements
for listing. A PSO can be ‘‘delisted’’ if
it is found to no longer meet the
requirements of the Patient Safety Act
and Patient Safety Rule, when a PSO
chooses to voluntarily relinquish its
status as a PSO for any reason, or when
the PSO’s listing expires. Section
3.108(d) of the Patient Safety Rule
requires AHRQ to provide public notice
when it removes an organization from
the list of federally approved PSOs.
Premerus PSO, LLC, PSO number
P0120, a component entity of Premerus,
Inc., chose to let its listing expire by not
seeking continued listing. Accordingly,
Premerus PSO, LLC was delisted
effective at 12:00 Midnight ET (2400) on
January 10, 2015.
More information on PSOs can be
obtained through AHRQ’s PSO Web site
at https://www.pso.AHRQ.gov/
index.html.
PO 00000
Number of
responses per
respondent
100
SUPPLEMENTARY INFORMATION:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
VerDate Sep<11>2014
Adult Donors
Improvement and Patient Safety, AHRQ,
540 Gaither Road, Rockville, MD 20850;
Telephone (toll free): (866) 403–3697;
Telephone (local): (301) 427–1111; TTY
(toll free): (866) 438–7231; TTY (local):
(301) 427–1130; Email: PSO@
AHRQ.hhs.gov.
[FR Doc. 2015–06565 Filed 3–20–15; 8:45 am]
SUMMARY:
Number of
respondents
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
an start-up exclusive commercial
license to practice the inventions
embodied in U.S. Patent Application
No. 62/034,995 entitled ‘‘Human
Monoclonal Antibodies Specific for 5T4
and Methods of Their Use’’ filed August
8, 20014 [HHS Ref. E–158–2014/0–US–
01] and all related continuing and
foreign patents/patent applications for
the technology family to Concortis, Inc.
The patent rights in these inventions
have been assigned to the Government
of the United States of America. The
prospective start-up exclusive
commercial license territory may be
worldwide and the field of use may be
limited to the development of 5T4
antibody drug conjugate therapeutics for
the treatment of human cancers using
Concortis’ proprietary conjugation
technologies.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before April
7, 2015 will be considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries,
comments, and other materials relating
to the contemplated exclusive
evaluation option license should be
directed to: Whitney Hastings, Ph.D.,
Senior Licensing and Patenting
Manager, Office of Technology Transfer,
National Institutes of Health, 6011
Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; Telephone:
(301) 451–7337; Facsimile: (301) 402–
0220; Email: hastingw@mail.nih.gov.
SUPPLEMENTARY INFORMATION: 5T4 is an
antigen expressed in a number of
SUMMARY:
E:\FR\FM\23MRN1.SGM
23MRN1
]]>Agencies
[Federal Register Volume 80, Number 55 (Monday, March 23, 2015)]
[Notices]
[Page 15220]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-06454]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Patient Safety Organizations: Expired Listing From Premerus PSO,
LLC
AGENCY: Agency for Healthcare Research and Quality (AHRQ), Department
of Health and Human Services (HHS).
ACTION: Notice of delisting.
-----------------------------------------------------------------------
SUMMARY: The Patient Safety and Quality Improvement Act of 2005, 42
U.S.C. 299b-21 to b-26, (Patient Safety Act) and the related Patient
Safety and Quality Improvement Final Rule, 42 CFR part 3 (Patient
Safety Rule), published in the Federal Register on November 21, 2008,
(73 FR 70732-70814), provide for the formation of Patient Safety
Organizations (PSOs), which collect, aggregate, and analyze
confidential information regarding the quality and safety of healthcare
delivery. The Patient Safety Rule authorizes AHRQ, on behalf of the
Secretary of HHS, to list as a PSO an entity that attests that it meets
the statutory and regulatory requirements for listing. A PSO can be
``delisted'' by the Secretary if it is found to no longer meet the
requirements of the Patient Safety Act and Patient Safety Rule, when a
PSO chooses to voluntarily relinquish its status as a PSO for any
reason, or when a PSO's listing expires. The listing from the Premerus
PSO, LLC has expired and AHRQ has delisted the PSO accordingly.
DATES: The directories for both listed and delisted PSOs are ongoing
and reviewed weekly by AHRQ. The delisting was effective at 12:00
Midnight ET (2400) on January 10, 2015.
ADDRESSES: Both directories can be accessed electronically at the
following HHS Web site: https://www.pso.AHRQ.gov/.
FOR FURTHER INFORMATION CONTACT: Eileen Hogan, Center for Quality
Improvement and Patient Safety, AHRQ, 540 Gaither Road, Rockville, MD
20850; Telephone (toll free): (866) 403-3697; Telephone (local): (301)
427-1111; TTY (toll free): (866) 438-7231; TTY (local): (301) 427-1130;
Email: PSO@AHRQ.hhs.gov.
SUPPLEMENTARY INFORMATION:
Background
The Patient Safety Act authorizes the listing of PSOs, which are
entities or component organizations whose mission and primary activity
are to conduct activities to improve patient safety and the quality of
health care delivery.
HHS issued the Patient Safety Rule to implement the Patient Safety
Act. AHRQ administers the provisions of the Patient Safety Act and
Patient Safety Rule relating to the listing and operation of PSOs. The
Patient Safety Rule authorizes AHRQ to list as a PSO an entity that
attests that it meets the statutory and regulatory requirements for
listing. A PSO can be ``delisted'' if it is found to no longer meet the
requirements of the Patient Safety Act and Patient Safety Rule, when a
PSO chooses to voluntarily relinquish its status as a PSO for any
reason, or when the PSO's listing expires. Section 3.108(d) of the
Patient Safety Rule requires AHRQ to provide public notice when it
removes an organization from the list of federally approved PSOs.
Premerus PSO, LLC, PSO number P0120, a component entity of Premerus,
Inc., chose to let its listing expire by not seeking continued listing.
Accordingly, Premerus PSO, LLC was delisted effective at 12:00 Midnight
ET (2400) on January 10, 2015.
More information on PSOs can be obtained through AHRQ's PSO Web
site at https://www.pso.AHRQ.gov/.
Dated: March 17, 2015.
Sharon B. Arnold,
Deputy Director, AHRQ.
[FR Doc. 2015-06454 Filed 3-20-15; 8:45 am]
BILLING CODE 4160-90-P
